SCHEMBL5887592

SCHEMBL5887592

COC1=C(c2ccc(OC)cc2)[CH]CC=C1c1ccccc1Cl

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABL1 P00519 1/20 0.39
ABCB1 P08183 1/20 0.39
BCR P11274 1/20 0.39
PTPN1 P18031 1/20 0.38
HTR1A P08908 1/20 0.37
HTR7 P34969 1/20 0.37
APP P05067 1/20 0.36
BACE1 P56817 1/20 0.36
HSP90AA1 P07900 1/20 0.36
HSP90AB1 P08238 1/20 0.36
NFE2L2 Q16236 2/20 0.35
RELA Q04206 1/20 0.35
HDAC4 P56524 1/20 0.35
HDAC2 Q92769 1/20 0.35
HDAC8 Q9BY41 1/20 0.35
MAPT P10636 3/20 0.35
NPC1 O15118 2/20 0.35
RAB9A P51151 2/20 0.35
ALDH1A1 P00352 1/20 0.35
LMNA P02545 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5887439 0.89 ABL1 (0.39) ABL1ABCB1BCRPTPN1HTR1A
SCHEMBL5887283 0.82 BACE1 (0.42) ABL1ABCB1BCRPTPN1APP
SCHEMBL5887134 0.82 ALOX5 (0.39) PTPN1BACE1MAPTNPC1RAB9A
SCHEMBL5887524 0.81 RAD51 (0.37) MAPTSMN1; SMN2
SCHEMBL5887387 0.78 LTA4H (0.51) PTPN1BACE1MAPTNPC1RAB9A
SCHEMBL5887229 0.77 ACHE (0.46) PTPN1APPBACE1RELAMAPT
SCHEMBL6047658 0.77 NPC1 (0.41) ABL1ABCB1BCRPTPN1HTR1A
SCHEMBL5887251 0.75 BACE1 (0.41) PTPN1APPBACE1MAPTNPC1
SCHEMBL5681041 0.74 ABL1 (0.60) ABL1ABCB1BCRPTPN1HTR1A
SCHEMBL5887281 0.73 LTA4H (0.49) PTPN1BACE1MAPTNPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7037931-B2 Corticotropin releasing factor moderator; analgesics; drug abruse, drug dependency; schizophrenia JANSSEN PHARMACEUTICA N.V. (BE) 2006-05-02 US disclosed
US-20050026903-A1 CCK-1 receptor modulators JANSSEN PHARMACEUTICA N.V. (BE) 2005-02-03 US disclosed
US-20050020565-A1 Pyrazole compound; gastrointestinal disorders; central nervous system disorders JONES TODD K (US) 2005-01-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050020565-A1 Pyrazole compound; gastrointestinal disorders; central nervous system disorders CCKAR, CCKBR, NPY1R ABL1 2767/4885ABCB1 859/4885BCR 1082/4885
US-20050026903-A1 CCK-1 receptor modulators CCKAR, CCKBR, GLP1R ABL1 2540/4885ABCB1 1319/4885BCR 1098/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.